STRO-007

STRO-007 is a site-specific antibody-drug conjugate (ADC) targeting B7-H3 (CD276), a transmembrane protein that is highly overexpressed in a wide range of solid tumors, including lung, prostate, and breast cancers, while exhibiting limited expression in normal tissues. Developed using Sutro Biopharma's proprietary XpressCF cell-free protein synthesis platform, STRO-007 is engineered to carry a single type of cytotoxic payload conjugated at precise, optimized locations on the antibody. This site-specific conjugation is designed to produce a homogeneous drug product with superior pharmacokinetics and a widened therapeutic index compared to traditional ADCs. The mechanism of action involves the binding of the ADC to B7-H3 on the tumor cell surface, followed by internalization and the subsequent release of its cytotoxic payload—typically a potent microtubule inhibitor such as a hemiasterlin derivative—which induces cell cycle arrest and apoptosis in the target-expressing cancer cells.

Other names

B7-H3 ADCB-7-H3 ADCB 7-H3 ADCCD276-targeted ADCCD-276-targeted ADCCD 276-targeted ADC